BF-30 effectively inhibits ciprofloxacin-resistant bacteria in vitro and in a rat model of vaginosis

Archives of Pharmacal Research

Volumn 37, Issue 7, 2014, Pages 927-936

  Wang, Jing ^a   Li, Bing ^a   Li, Yang ^a   Dou, Jie ^a   Hao, Qingru ^a   Tian, Yuwei ^a   Wang, Hui ^a   Zhou, Changlin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antimicrobial activity; BF 30; Ciprofloxacin resistant bacteria; Cytoplasmic membrane permeability; DNA binding; Vaginosis

Indexed keywords

CATHELICIDIN BF 30; CIPROFLOXACIN; GENOMIC DNA; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; CATHELICIDIN; CATHELICIDIN BF, BUNGARUS FASCIATUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ESCHERICHIA COLI; FEMALE; IN VITRO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN SYNTHESIS; RAT; STAPHYLOCOCCUS AUREUS; VAGINAL SECRETION; VAGINITIS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; PATHOLOGY; TREATMENT OUTCOME; VAGINOSIS, BACTERIAL;

ANIMALS; CATHELICIDINS; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FEMALE; RATS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VAGINOSIS, BACTERIAL;

EID: 84902352507     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0248-6     Document Type: Article

References (35)

1. Belley, A., E. Neesham-Grenon, G. McKay, F.F. Arhin, R. Harris, T. Beveridge, T.R. Parr Jr, and G. Moeck. 2009. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrobial Agents and Chemotherapy 53: 918-925.
2. Brogden, K.A. 2005. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nature Reviews Microbiology 3: 238-250. (Pubitemid 40298223)
3. Chen, W., B. Yang, H. Zhou, L. Sun, J. Dou, H. Qian, W. Huang, Y. Mei, and J. Han. 2011. Structure-activity relationships of a snake cathelicidin-related peptide, BF-15. Peptides 32: 2497-2503.
4. De Smet, K., and R. Contreras. 2005. Human antimicrobial peptides: Defensins, cathelicidins and histatins. Biotechnology Letters 27: 1337-1347. (Pubitemid 41805626)
5. Deng, L., X. Pan, Y. Wang, L. Wang, X. Zhou, M. Li, Y. Feng, Q. Wu, B. Wang, and N. Huang. 2009. Hemoglobin and its derived peptides may play a role in the antibacterial mechanism of the vagina. Human Reproduction 24: 211-218.
6. Di Nardo, A., K. Yamasaki, R.A. Dorschner, Y. Lai, and R.L. Gallo. 2008. Mast cell cathelicidin antimicrobial peptide prevents invasive group A Streptococcus infection of the skin. The Journal of Immunology 180: 7565-7573.
7. Dürr, U.H., U.S. Sudheendra, and A. Ramamoorthy. 2006. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochimica et Biophysica Acta 1758: 1408-1425. (Pubitemid 44436081)
8. Elsbach, P. 2003. What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses? Journal of Clinical Investigation 111: 1643-1645. (Pubitemid 38057744)
9. Guo, Y., J. Wang, G. Niu, W. Shui, Y. Sun, H. Zhou, Y. Zhang, C. Yang, Z. Lou, and Z. Rao. 2011. A structural view of the antibiotic degradation enzyme NDM-1 from a superbug. Protein Cell 2: 384-394.
10. Hancock, R.E., and R. Lehrer. 1998. Cationic peptides: A new source of antibiotics. Trends in Biotechnology 16: 82-88. (Pubitemid 28055477)
11. Hao, G., Y. Shi, Y. Tang, and G. Le. 2009. The membrane action mechanism of analogs of the antimicrobial peptide Buforin 2. Peptides 30: 1421-1427.
12. Hao, Q., H. Wang, J. Wang, J. Dou, M. Zhang, W. Zhou, and C. Zhou. 2013. Effective antimicrobial activity of Cbf-K16 and Cbf-A 7A13 against NDM-1-carrying Escherichia coli by DNA binding after penetrating the cytoplasmic membrane in vitro. Journal of Peptide Science 19: 173-180.
13. Huo, L., K. Zhang, J. Ling, Z. Peng, X. Huang, H. Liu, and L. Gu. 2011. Antimicrobial and DNA-binding activities of the peptide fragments of human lactoferrin and histatin 5 against Streptococcus mutans. Archives of Oral Biology 56: 869-876.
14. Izadpanah, A., and R.L. Gallo. 2005. Antimicrobial peptides. Journal of the American Academy of Dermatology 52: 381-390.
15. Jacoby, T.S., R.S. Kuchenbecker, R.P. Dos Santos, L. Magedanz, P. Guzatto, and L.B. Moreira. 2010. Impact of hospital-wide infection rate, invasive procedures use and antimicrobial consumption on bacterial resistance inside an intensive care unit. Journal of Hospital Infection 75: 23-27.
16. Kanthawong, S., K. Nazmi, S. Wongratanacheewin, J.G. Bolscher, V. Wuthiekanun, and S. Taweechaisupapong. 2009. In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides. International Journal of Antimicrobial Agents 34: 309-314.
17. Kasetty, G., P. Papareddy, M. Kalle, V. Rydengård, M. Mörgelin, B. Albiger, M. Malmsten, and A. Schmidtchen. 2011. Structureactivity studies and therapeutic potential of host defense peptides of human thrombin. Antimicrobial Agents and Chemotherapy 55: 2880-2890.
18. Kumarasamy, K.K., M.A. Toleman, T.R. Walsh, J. Bagaria, F. Butt, R. Balakrishnan, U. Chaudhary, M. Doumith, C.G. Giske, S. Irfan, P. Krishnan, A.V. Kumar, S. Maharjan, S. Mushtaq, T. Noorie, D.L. Paterson, A. Pearson, C. Perry, R. Pike, B. Rao, U. Ray, J.B. Sarma, M. Sharma, E. Sheridan, M.A. Thirunarayan, J. Turton, S. Upadhyay, M. Warner, W. Welfare, D.M. Livermore, and N. Woodford. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, andepidemiological study. The Lancet Infectious Diseases 10: 597-602.
19. Madhuri, Shireen, T., Venugopal, S.K., Ghosh, D., Gadepalli, R., Dhawan, B., and Mukhopadhyay, K. 2009. In vitro antimicrobial activity of alpha-melanocyte stimulating hormone against major human pathogen Staphylococcus aureus. Peptides 30:1627-1635.
20. Makobongo, M.O., T. Kovachi, H. Gancz, A. Mor, and D.S. Merrell. 2009. In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori. Antimicrobial Agents and Chemotherapy 53: 4231-4239.
21. Marr, A.K., W.J. Gooderham, and R.E. Hancock. 2006. Antibacterial peptides for therapeutic use: Obstacles and realistic outlook. Current Opinion in Pharmacology 6: 468-472. (Pubitemid 44340665)
22. Maurya, I.K., S. Pathak, M. Sharma, H. Sanwal, P. Chaudhary, S. Tupe, M. Deshpande, V.S. Chauhan, and R. Prasad. 2011. Antifungal activity of novel synthetic peptides by accumulation of reactive oxygen species (ROS) and disruption of cell wall against Candida albicans. Peptides 32: 1732-1740.
23. McGrath, D.M., E.M. Barbu, W.H. Driessen, T.M. Lasco, J.J. Tarrand, P.C. Okhuysen, D.P. Kontoyiannis, R.L. Sidman, R. Pasqualini, and W. Arap. 2013. Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimetic. Proceedings of the National Academy of Sciences 110: 3477-3482.
24. Powers, J.P., and R.E. Hancock. 2003. The relationship between peptide structure and antibacterial activity. Peptides 24: 1681-1691. (Pubitemid 38198075)
25. Rajaei, A., M. Barzegar, A.M. Mobarez, M.A. Sahari, and Z.H. Esfahani. 2010. Antioxidant, anti-microbial and antimutagenicity activities of pistachio (Pistachia vera) green hull extract. Food and Chemical Toxicology 48: 107-112.
26. Scott, A., Weldon, S., Buchanan, P. J., Schock, B., Ernst, R.K., McAuley, D.F., Tunney, M.M., Irwin, C.R., Elborn, J.S., and Taggart, C.C. 2011. Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS One 6:e26525.
27. Singh, M., and K. Mukhopadhyay. 2011. C-terminal amino acids of alpha-melanocyte-stimulating hormone are requisite for its antibacterial activity against Staphylococcus aureus . Antimicrobial Agents and Chemotherapy 55: 1920-1929.
28. Sobel, J.D. 1990. Vaginal infections in adult women. The Medical Clinics of North America 74: 1573-1602. (Pubitemid 20384863)
29. Solé, M., C. Pitart, I. Roca, A. Fàbrega, P. Salvador, L. Muñoz, I. Oliveira, J. Gascón, F. Marco, and J. Vila. 2011. First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrobial Agents and Chemotherapy 55: 4402-4404.
30. Spiegel, C.A., R. Amsel, and K.K. Holmes. 1983. Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. Journal of Clinical Microbiology 18: 170-177. (Pubitemid 13056830)
31. Spinillo, A., A.M. Bernuzzi, C. Cevini, R. Gulminetti, S. Luzi, and A. De Santolo. 1997. The relationship of bacterial vaginosis, Candida and Trichomonas infection to symptomatic vaginitis inpostmenopausal women attending a vaginitis clinic. Maturitas 27: 253-260. (Pubitemid 27356258)
32. Wang, H., M. Ke, Y. Tian, J. Wang, B. Li, Y. Wang, and C. Zhou. 2013. BF-30 selectively inhibits melanoma cell proliferation via cytoplasmic membrane permeabilization and DNA-binding in vitro and in B16F10-bearing mice. European Journal of Pharmacology 707: 1-10.
33. Wang, M., H. Wang, Y. Tang, D. Kang, Y. Gao, M. Ke, J. Dou, T. Xi, and C. Zhou. 2011. Effective inhibition of a Strongylocentrotus nudus eggs polysaccharide against hepatocellular carcinoma ismediated via immunoregulation in vivo. Immunology Letters 141: 74-82.
34. Wang, Y., J. Hong, X. Liu, H. Yang, R. Liu, J. Wu, A. Wang, D. Lin, and R. Lai. 2008. Snake cathelicidin from Bungarus fasciatus is a potent peptide antibiotics. PLoS ONE 3: e3217.
35. Zhou, H., J. Dou, J. Wang, L. Chen, H. Wang, W. Zhou, Y. Li, and C. Zhou. 2011. The antibacterial activity of BF-30 in vitro and in infected burned rats is through interference with cytoplasmic-membrane integrity. Peptides 32: 1131-1138.